130 results about "HaCaT" patented technology

The invention discloses an in-vitro evaluation cell model of skin sensitization of a compound and a construction method of the cell model. The construction method of the cell model comprises the following steps of: designing and constructing an sgRNA (small guide ribonucleic acid) expression vector with CRISPR / Cas9 (clustered regularly interspaced short palindromic repeats / CRISPR associated protein 9), designing and constructing a homologous recombinant vector capable of knocking a reporter gene connected with a spontaneous lysis peptide sequence into an expression cassette of an HMOX1 (heme oxygenase (decycling) 1) gene, and cotransfecting a cell with the homologous recombinant vector, hCas9 (humanized Cas9) plasmid and the sgRNA expression vector for monoclone enlarging culture to form the cell model. The HaCaT cell model with a luciferase gene knocked in before a termination codon of the HMOX1 gene by a combined CRISPR / CAS9 cell monoclone technology. The cell model achieves synchronous expression of the luciferase gene and the HMOX1 gene, so that a sensitization compound and a non-sensitization compound are effectively differentiated, and the more specific and sensitive cell model is provided for compound sensitization studies.

The invention belongs to the cosmetics field, and particularly relates to a composition with after-sun repair, antioxidant and whitening effect and its preparation method. The composition is preparedby taking tricholoma matsutake, lucid ganoderma, tremella and other fungus drugs. The composition is prepared from, by weight, 0.5-5 parts of tricholoma matsutake, 0.5-5 parts of lucid ganoderma, and0.5-5 parts of tremella. The composition takes three nature mushroom type drug extractives of tricholoma matsutake, lucid ganoderma, tremella as main active matters; the prepared composition can be applied to skincare; compared with the independent use of tricholoma matsutake, lucid ganoderma, or tremella, the composition can obviously lighten the light injuiry of HaCaT cell induced by UVB, and has obvious skin light aging resistance; therefore, the composition has the after-sun repair effect; the composition also can effectively remove DPPH free radicals and hydroxyl radical, good antioxidantand clear anti-aging effect. The composition can obviously inhibit activity of monophenyl oxidase, inhibit generation of melanin in melanoma cell, and further play the whitening effect; therefore, the composition has clear whitening effect.

The invention provides a carbohydrate composition with a wound healing promoting effect and application of the carbohydrate composition. The carbohydrate composition contains at least five types of carbohydrate including carboxymethyl chitosan, rhizoma bletillae polysaccharides, fucoidan from fucus vesiculosus, heparan sulfate, chondroitin sulfate, oligosaccharides of hyaluronan and gulose aldehyde acid oligosaccharides. The carbohydrate composition and the application have the advantages that VEGFA (vascular endothelial growth factor A), FGF2 (fibroblast growth factor 2) and VE-cadherin protein mRNA (messenger ribonucleic acid) expression can be obviously improved by the carbohydrate composition, VEGF (vascular endothelial growth factor) secretion and skin fibroblast (HSF) and human immortalized keratinocyte (HaCaT) proliferation can be obviously promoted by the carbohydrate composition, and the obvious wound healing promoting effect can be realized by the carbohydrate composition; raw materials required by the carbohydrate composition are easily available, composition methods for the carbohydrate composition are simple, the carbohydrate composition is low in cost, easy to industrialize and wide in application range, and the like.

The invention discloses a protection effect of cyanidin-3-glucoside (C3G) for UVB (ultraviolet B)-induced cell injury. The protection effect particularly includes that generation of ROS (reactive oxygen species) of HaCaT cells due to UVB can be reduced by the C3G, accordingly, antioxidant effects can be realized, DNA (deoxyribonucleic acid) can be protected against injury, the survival rate of the HaCaT cells can be increased after the UVB irradiates on the HaCaT cells, and apoptosis reducing effects and the like can be realized. The protection effect has the advantages that the oxidation injury of the selected representative HaCaT cells which are cultivated in vitro is induced by means of UVB irradiation, light injury models of epidermal cells due to ultraviolet rays are imitated, then the C3G is used as a light injury protector, effects and relevant channels of the C3G for relieving UVB injury of the HaCaT cells are evaluated, the protection effect, action mechanisms and the safety of the C3G for light injury of skins are investigated, and accordingly theoretical foundation is laid for clinically effectively preventing and treating light injury of the skins and studying ultraviolet radiation injury protection action mechanisms of natural plant antioxidants.

The invention discloses application of tanshinone I in preparation of a medicine for treating psoriasis. The medicine comprises therapeutically effective amount of tanshinone I and medically acceptable vectors, wherein the content of tanshinone I is 1-99wt%. The tanshinone I can be prepared into clinically or medically acceptable preparations, including commonly-used oral solid preparations such as capsules and tablets, or external preparations such as emulsifiable paste or cream and gels; the preparations can be applied to a patient needing treatment in external use and oral ways; and the tanshinone I has an obvious effect of inhibiting HaCaT cell proliferation, and can be applied to preparation of the medicine for treating psoriasis. The medicine prepared by the tanshinone I has the beneficial effects that the remarkable effects are verified in animal experiments and clinical tests, and the safety is high; and the medicine is a novel medicine for treating the psoriasis, and has a good development prospect.

The invention discloses lactobacillus plantarum capable of improving facial sensitive skin and repairing skin barriers, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a strain of lactobacillus plantarum CCFM1158, and the lactobacillus plantarum CCFM1158 can relieve human cell barrier injury, which is specifically embodied in that (1) the survival rate of SDS-induced HaCaT cells is obviously improved; (2) the barrier damage caused by the SDS-induced HaCaT cells is obviously improved; (3) the cell migration capability is obviously promoted; and (4) the strain can effectively promote the expression of a natural moisturizing factor and a barrier integrity factor FLG, so that the lactobacillus plantarum CCFM1158 has a huge application prospect in preparation of products for preventing or treating skin barrier injury.

The invention provides a skin safety evaluation method on nanometer titanium dioxide based on HaCaT cells, and belongs to the field of external material detection. The method comprises the following steps that the HaCaT cells are sequentially treated by nanometer titanium dioxide solutions with different concentrations and ultraviolet rays, and a cell survival rate is tested; the concentration ofthe nanometer titanium dioxide solution with the HaCaT cell survival rate reaching 50 to 90 percent is selected to be used as potential dangerous concentration; the ultraviolet ray treatment is combined, so that a sialic acid expression level in the cells and an ROS level in the cells generate constant change; finally, the influence of the potential dangerous concentration of nanometer titanium dioxide on the cell injury degree can be judged through detecting the change of the expression level of the sialic acid, so that a set of standard nanometer titanium dioxide skin safety evaluation method is obtained. The invention provides the reliable scientific basis for the safe use of the nanometer titanium dioxide and also provides reference for the safety evaluation of other nanometer materials.

The present invention relates to a novel analogue antibiotic peptide derived from a CM-MA peptide and a use thereof. Specifically, the novel antibiotic peptides represented by SEQ. ID. NO: 2 to SEQ. ID. NO: 7 (CAM 1 to CMA 6) were synthesized by using a CM-MA antibiotic peptide, in which amphiphilic cecropin A (CA) and magainin 2 (MA) are conjugated, as a template. The synthesized antibiotic peptide exhibits antibiotic activity on gram-positive bacteria and gram-negative bacteria and low cytotoxicity on human red blood cells and human normal cell lines (HaCaT), and thus the antibiotic peptide of the present invention can be favorably used as an active ingredient of an antibiotic agent, a cosmetic composition, a food additive, a feed additive, and a biological pesticide.

The invention discloses a construction method of a tissue engineering epidermis model. The construction method comprises the following steps of: A. making a thermoplastic non-woven fabric into a disc-shaped support by using a hot-pressing method; B. by taking mulberry silks as raw materials, degumming, dissolving, dialyzing and concentrating so as to prepare a silk fibroin solution; C. soaking the disc-shaped non-woven fabric support by using the prepared silk fibroin solution, wherein the concentration of the silk fibroin solution is 2 to 10%, and then carrying out vacuum drying and absolute ethyl alcohol aftertreatment; D. inoculating a human epidermis cell strain Hacat, wherein the inoculum density of the Hacat cell is 10<4>-10<5> / ml, carrying out gas-liquid surface cultivation, and proliferating so as to form a lamellar structure, thus constructing the tissue engineering epidermis model. The construction method can be used for solving the shortcoming of the conventional tissue engineering epidermis model that a support is prone to shrink in a cell cultivation process; the edge of the non-woven fabric is fused and bonded by the hot-pressing of the non-woven fabric, so that the problem that the side surface of the constructed non-woven fabric leaks in detection is avoided.

The invention relates to application of dendrobium candidum polysaccharide in preparing a drug for promoting hair growth, wherein the dendrobium candidum polysaccharide in the drug is 0.1%-5% by weight. The dendrobium candidum polysaccharide in the drug disclosed by the invention can be used for regulating up expression of a vascular endothelial growth factor (VEGF) gene in a keratoderma forming cell (HaCaT cell) blood vessel, so that the effect of prompting the hair growth is achieved.

The invention provides application of linoleic acid in preparing a human papillomavirus resisting (HPV) medicament. In the application, the linoleic acid can be a soluble solution prepared by using linoleic acid, or an extract extracted from natural plants. The linoleic acid has trend of inhibiting Hacat cell multiplication, and the inhibiting trend of the linoleic acid increases along with extension of the acting time of the medicament. Polymerase chain reaction experiments and cytological experiments prove that the linoleic acid has HPV resistance, and plays a role in treating condyloma acuminata (CA).

The invention discloses novel medicinal application of icariin, and particularly relates to application of icariin in preparation of medicine for treating dermatitis. TNF-alpha / IFN-gamma-irritated skin keratinocytes (HaCaT cells) are adopted as an in-vitro dermatitis model and subjected to icariin intervention. A result shows that icariin can effectively inhibit rising of the level of HaCaT cell inflammatory factors (IL-6, IL-1beta and IL-8) which are induced by TNF-alpha / IFN-gamma; the skin inflammatory resisting effect of icarriin is related to inhibition on expression of phosphorylation p38 and phosphorylation ERK; the skin inflammatory resisting effect of icarriin is related to improvement of cortisol secretion of the skin keratinocytes. Icariin can be used for preparing the medicine for treating the dermatitis.

The invention discloses an application of glaucocalyxin and a compound with a similar structure to glaucocalyxin in preparing anti-inflammation and anti-light-aging products, and relates to the technical field of medicines and cosmetics in order to solve the problem that a study of glaucocalyxin and the compound with the similar structure to glaucocalyxin in terms of inflammation resistance and light aging resistance is unavailable. A good anti-inflammatory effect of glaucocalyxin and the compound with the similar structure is verified by taking LPS (lipopolysaccharide) induced release of NO and IL-6 (interleukin 6) from RAW264.7 cells as a target; glaucocalyxin and the compound with the similar structure are proven to have good application prospects in preparing the anti-inflammation products; a good anti-light-aging effect of glaucocalyxin and the compound with the similar structure is verified by taking UVB induced HaCaT cell damage and IL-6 secretion as a target; and glaucocalyxinand the compound with the similar structure are proven to have good application prospects in preparing the anti-light-aging products.

The invention belongs to the technical field of medicine and discloses the application of diphenylheptane compounds in the preparation of medicines or food for preventing and treating psoriasis. The diphenylheptane compound has the structure shown in formula I: Wherein, the 4-5 position of the diphenylheptane compound is a single bond or a double bond, and the 6-7 position is a single bond or a double bond; R 1 is double bond oxygen or acetoxy; R 2 is hydrogen, hydroxy or methoxy. The diphenylheptane compound of the invention has inhibitory effect on the proliferation of human skin T cell lymphoma cell line HH cells and human immortalized epidermal keratinogenic cell line HaCaT cells, and can be applied to the preparation of medicines or food for preventing and treating psoriasis.

The invention discloses an application of an exosome in preparation of drugs or cosmetics for repairing skin injury, belonging to the technical field of skin treatment. In order to solve the problem of skin injury, the exosome provided by the invention is obtained through the following steps: separating mesenchymal stem cells from primary cornu cervi pantotrichum tissues; and carrying out in-vitroamplification culture, collecting a cell culture solution, and carrying out separation and extraction so as to obtain an antler mesenchymal stem cell-derived exosome. The exosome provided by the invention is proved to be able to inhibit LPS induced inflammatory response of HaCat cells through an NLRP3 inflammasome signaling pathway, accelerate wound repair of a mouse model with skin injury and relieve inflammatory response. The exosome provided by the invention can be used for preparing the drugs or the cosmetics for treating skin injury repairing.

The invention relates to the technical field of baby washing and caring, and discloses a composition for reducing irritation of a surfactant to skin and application of the composition. The compositiondisclosed by the invention is prepared from vitamin E, dipotassium glycyrrhizinate and D-panthenol. According to the composition, vitamin E, dipotassium glycyrrhizinate and panthenol are used as theirritation-reducing composition adapted to disodium coco-glucoside citrate, so that the toxicity to HacaT cells and the irritation to eyes can be remarkably reduced; and in comparison with other surfactants for irritation reduction, the composition has high concentration adaptability to disodium coco-glucoside citrate, and can be applied to washing and caring products using disodium coco-glucosidecitrate, particularly to washing and caring products for infants and children.

The invention discloses application of curcumin in preparation of medicine for treating psoriasis. The medicine comprises an effective amount of curcumin and a pharmaceutically acceptable carrier, wherein the weight content of the curcumin is 1-99%. The curcumin and the carrier are prepared into clinically or pharmaceutically acceptable preparation which are conventional oral solid preparations such as capsules or tablets or external preparation such as ointment, cream and gel; the preparation are applied to patients requiring treatment through external or oral approach and have obvious effect on control on HaCaT cell proferation; and the curcumin can be used for preparing the medicine for treating psoriasis. Proven by animal experiments and clinical tests, curcumin has an obvious effect and good safety; and curcumin is a novel medicine for treating psoriasis, and has good development prospect.

The invention relates to the technical field of biomedicine, and particularly discloses an oligopeptide and an active peptide composition and application of the oligopeptide and the active peptide composition in preparation of a product with an anti-inflammatory effect. The oligopeptide has a structure as shown in a formula I which is described in the specification. The active peptide composition comprises the oligopeptide with the structure as shown in the formula I and active cyclic peptide with the structure as shown in a formula II; and experiments show that both the oligopeptide bifidobacterium oligopeptide-alpha and the active peptide saccharomyces cerevisiae cyclic peptide-beta can inhibit HaCaT cell inflammatory injury and apoptosis caused by LPS exposure. Therefore, the bifidobacterium oligopeptide-alpha, the saccharomyces cerevisiae cyclopeptide-beta and the composition of the bifidobacterium oligopeptide-alpha and the saccharomyces cerevisiae cyclopeptide-beta can be used as active substances in cosmetics, skin care products, foods, health care products or medicines to play an anti-inflammatory role.

The invention relates to an application of ruthenium pyridine (II) complexes as antitumor drugs. In particular, the inhibition effect of two ruthenium pyridine (II) complexes on growth of a highly invasive human breast cancer cell line (MDA-MB-231), a hepatoma carcinoma cell (HepG2), a human esophageal carcinoma cell (EC-1), a human breast cancer cell (MCF-7) and a normal breast epithelial cell (HAcat) is tested. The result shows that the complexes have inhibiting effects on four cancer cells to different extents, and in particular, the complex I has strong inhibiting effect on the MDA-MB-231 and the complex II has a very remarkable inhibiting effect on MDA-MB-231 and HepG2. The two complexes have weak toxicity to the HAcat and show good selectivity.

The invention discloses lactobacillus paracasei capable of inhibiting abnormal proliferation of HaCaT cells, and belongs to the technical field of microorganisms and medicines. The invention providesa lactobacillus paracasei CCFM1147, and the lactobacillus paracasei CCFM1147 can alleviate psoriasis, which is specifically embodied in that the excessive proliferation of psoriasis-like cortical forming cells is inhibited; the activation of an NF-kB signal path in psoriasis-like cortical forming cells is inhibited; the level of proinflammatory factor IL-6 in psoriasis-like cortical forming cellsis reduced; the level of proinflammatory factor IL-8 in psoriasis-like cortical forming cells is reduced; and therefore, the lactobacillus paracasei CCFM1147 has a huge application prospect in the preparation of products (such as daily chemical products or medicines) for preventing and / or treating psoriasis.

The invention relates to application of an ALDH3A1 / IL-17 axis in preparation of a medicine for treating refractory ulcer. According to the invention, proteomics is combined with biological information analysis, and experimental verification is combined for use, so the protein expression of ALDH3A1 in a wound surface of a db / db diabetic mouse is reduced; and by overexpressing ALDH3A1 expression in HaCaT cells, proliferation of the cells is increased, inflammatory infiltration is relieved, and an IL-17 pathway is remarkably inhibited. It is prompted in the invention that ALDH3A1 can improve chronic inflammation, promote cell proliferation and heal wounds by inhibiting downstream IL-17 signal channels, and the targeted ALDH3A1 / IL-17 axis can be used as a novel treatment method and is used for treating refractory ulcers, chronic inflammation after injury, infection and other types of wounds in the future.

The invention discloses a traditional Chinese medicine composition for preventing and treating skin lesion aging. The traditional Chinese medicine composition is prepared from 10-15 parts of herba siegesbeckiae extract, 15-25 parts of flos farfarae extract, 5-15 parts of licorice extract and 5-15 parts of radix angelica sinensis extract. The herba siegesbeckiae extract, the flos farfarae extract, the licorice extract and the radix angelica sinensis extract are prepared through the following method comprising the steps that herba siegesbeckiae, flos farfarae, liquorice roots and radix angelica sinensis are subjected to reflux extraction 1-6 times with 30-100% ethyl alcohol, the use amount of a solvent is 1-15 times of the weight of the medicinal materials every time, and the extraction time ranges from 0.5 h to 10 h every time; extraction solutions are combined and filtered, ethyl alcohol is recycled, concentration and drying are carried out, and then the traditional Chinese medicine composition is obtained. The traditional Chinese medicine composition has the functions of resisting oxidative stress and inflammation, the level of glutathione in human epidermis HaCaT cells can be increased, arsenic induced cytotoxicity is resisted, forming of arsenic induced reactive oxide species is inhibited, and the traditional Chinese medicine composition can be used for preparing medicine or cosmetics for preventing and treating skin injuries and inflammation lesion and delaying skin aging.

The invention belongs to the field of medicine and cosmetics and discloses application of dihydromyricetin in the preparation of skin-care products or drugs for preventing and treating optical skin injuries.The skin-care product prepared from dihydromyricetin for preventing and treating optical skin injuries is sun screen, wherein the sun screen comprises: water, propylene glycol, glycerol, trehalose, oat beta-glucan, dihydromyricetin, C20-22 alkyl phosphate, polydimethylsiloxane, isononyl isononanoate and methylparaben.Experiments with a UVA induced HaCaT cell model proves that dihydromyricetin is effective in inhibiting cell ROS generation, reducing expression of apoptosis factors and inflammatory factors, reliving oxidization damage to cells, reducing inflammatory reaction of cells and cell apoptosis and preventing and treating optical skin injuries.The dihydromyricetin has a promising development prospect in the preparation of skin-care products or drugs for preventing and treating optical skin injuries.

The invention relates to preparation of an sgRNA and HaCaT cell model targeting a human genome sequence at a high-frequency integration site of high-risk HPV. According to the invention, specific sgRNAs are respectively designed for integration sites of HPV16 in a 13q22 region and an 8q24 region, and sgRNA double-stranded DNA is obtained; the sgRNA double-stranded primers are connected with a CRISPR / Cas9 vector to obtain an sgRNA expression vector, and sgRNA targeting plasmids are obtained through screening; a linear Donor fragment containing a high-risk human papilloma virus HPV gene is synthesized by using cloning construction and PCR amplification respectively, and the linear Donor fragment is used for co-transfecting HaCaT cells with the sgRNA targeting plasmids to obtain an HPV gene fixed-point integrated HaCaT cell model. According to the invention, the cell model integrated by HPV16 and HPV18 at high-frequency sites of a human genome is established by using a CRISPR / Cas technology, so that growth and proliferation of HaCaT cells are promoted, and a new method is provided for mechanism research of high-risk HPV integration in cervical cancer pathogenesis.

The invention discloses bacillus subtilis for improving the yield of traditional Chinese medicine polysaccharide and regulating skin barrier and immunity, and belongs to the field of fermentation engineering. Traditional Chinese medicine raw materials are used as a unique carbon source, proliferation factors and microelements beneficial for promoting proliferation of bacillus subtilis are added, the bacillus subtilis can rapidly proliferate in Dendrobium nobile Lindl or radix astragali raw material fermentation liquor, fermentation is conducted for certain time in the mode, the proliferation of the bacillus subtilis in the fermentation liquor exceeds 10 < 9 > cfu / mL, the content of the traditional Chinese medicine polysaccharide extracted after fermentation is increased by 1.13-1.72 times if being compared with the extraction rate of the traditional Chinese medicine polysaccharide extracted without fermentation, and the content of the traditional Chinese medicine polysaccharide extracted after fermentation is remarkably increased if being compared with the unfermented polysaccharide on the aspects of skin barrier repair and immunoregulation, so that the cell survival rate of SDS-induced HaCaT is remarkably increased, and the NO content in LPS-induced cells is reduced.

The invention belongs to the technical field of medicaments for skin diseases, and discloses a medicine for improving symptoms of acne rosacea, an animal model of the medicine and a construction method of the animal model. A BALB / C mouse of 7 weeks old is used, subcutaneous injection of LL37 polypeptide is performed twice each day, injection is performed for 2 days, and acne rosacea skin injury isinduced to make a model of the acne rosacea. As for the animal model, the mouse is subjected to intragastric administration of tranexamic acid 5 days in advance, a medicine control group is subjectedto intragastric administration of a PBS buffer solution, and 6-7 days after the intragastric administration, acne rosacea skin injury is induced. Through the adoption of an LL37 induced mouse model and a HaCaT cell model, the influence of TXA on the acne rosacea and the molecular mechanism of the TXA are assessed; through TXA treatment, the acne rosacea symptoms are obviously improved; and in addition, the TXA reduces the expression level of congenital immunity genes (TLR2, KLK5 and Camp) and neutral granulocyte related genes in acne rosacea sample lesion.

The present invention relates to novel pterocarpan compound or pharmaceutically acceptable salt thereof and a composition for the prevention or treatment of metabolic disease or complications thereof comprising the same as an active ingredient. The novel pterocarpan compound of the present invention isolated from soybean leaves inhibits α-glucosidase activity and hACAT activity, and suppresses LDL-oxidation efficiently. Therefore, the compound of the present invention not only can be effectively used for the prevention or treatment of metabolic disease or complications thereof but also can be effectively used as an anti-oxidative composition owing to its excellent anti-oxidative activity.

Melatonin, which can be produced in the skin, exerts a protective effect against damage induced by ultraviolet radiation (UVR). The present study investigated the effect of UVB, the most damaging component of UVR, on melatonin metabolism in HaCaT keratinocytes and in a cell-free system. Four metabolites were identified by HPLC and LC-MS: 6-hydroxymelatonin, AFMK, 2-hydroxymelatonin (the main intermediate between melatonin and AFMK) and 4-hydroxymelatonin. Concentrations of these photoproducts were directly proportional to UVR-dose and to melatonin substrate content, and their accumulation was time dependent. The UVR-dependent increase of AFMK and 2-hydroxymelatonin was also detected in keratinocytes, where it was accompanied by simultaneous consumption of intracellular melatonin. Of note, melatonin and its two major metabolites, 2-hydroxymelatonin and AFMK, were also detected in untreated keratinocytes, neither irradiated nor preincubated with melatonin. Thus, intracellular melatonin metabolism is enhanced under exposure to UVR. The additional biological activity of these individual melatonin metabolites increases the spectrum of potential actions of the recently identified cutaneous melatoninergic system.

A theaflavin composition comprising: theaflavin-3 '-gallate, or a separation mixture of theaflavin-3 '-gallate and one or more of theaflavin, theaflavin-3'-gallate or theaflavin-3, 3 '-gallate, or salt or derivative, hydrate or solvent compound of theaflavin-3 '-gallate capable of being obtained in the field of skin care products, and a skin care product carrier or a pharmaceutically acceptable carrier. The theaflavin composition can improve the activity of antioxidant enzyme, reduce the content of MDA and ROS, repair mitochondrial membrane potential to a certain extent and further reduce oxidative damage of UVB radiation to cells, thereby resisting photoaging damage of ultraviolet radiation to human skin. On the other hand, theaflavin-3'-gallate TF3 'G can effectively inhibit inflammatoryresponse caused by UVB radiation and reduce generation of HaCaT intracellular aggregates, and has a wide prospect in preparation of skin care products or drugs for preventing photoaging.

The invention provides an anti-HPV (human papillomavirus) medicine screening model, and a construction method and application thereof. The medicine screening model is a HaCaT cell (cell model I) or aHaCaT cell (cell model II), wherein the HaCaT cell (cell model I) includes HPV1 circular DNA (deoxyribonucleic acid) and carries reporter gene plasmids, and the HaCaT cell (cell model II) includes HPV11 circular DNA (deoxyribonucleic acid) and carries the reporter gene plasmids. The construction method for the cell model comprises the preparation of the HPV circular DNA, quality control detection,free HPV amplification detection and the absolute quantitative detection of a copy number. The above application is that by detecting a direct anti-proliferation function for model cells and an inhibition function for HPV genome DNA replication after a medicine is applied, medicines capable of resisting the activities of HPV1 and HPV11 can be screened. A system formed by the cell model can be used for screening treatment medicines for skin low-risk type HPV (HPV1) and mucosa low-risk type HPV (HPV11), and an application prospect is wide.